Baxter Bros Inc. Lowers Stake in Pfizer Inc. (NYSE:PFE)

Baxter Bros Inc. lessened its stake in Pfizer Inc. (NYSE:PFE) by 2.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 62,510 shares of the biopharmaceutical company’s stock after selling 1,409 shares during the period. Baxter Bros Inc.’s holdings in Pfizer were worth $1,658,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. PKS Advisory Services LLC bought a new stake in shares of Pfizer in the 4th quarter valued at about $324,000. Zions Bancorporation N.A. boosted its position in Pfizer by 3.6% during the 4th quarter. Zions Bancorporation N.A. now owns 212,680 shares of the biopharmaceutical company’s stock valued at $5,642,000 after acquiring an additional 7,374 shares in the last quarter. Modern Wealth Management LLC raised its position in shares of Pfizer by 48.7% in the 4th quarter. Modern Wealth Management LLC now owns 42,336 shares of the biopharmaceutical company’s stock worth $1,095,000 after acquiring an additional 13,865 shares in the last quarter. Segall Bryant & Hamill LLC lifted its stake in shares of Pfizer by 4.3% during the 4th quarter. Segall Bryant & Hamill LLC now owns 76,539 shares of the biopharmaceutical company’s stock worth $2,031,000 after purchasing an additional 3,177 shares during the last quarter. Finally, CoreFirst Bank & Trust purchased a new stake in shares of Pfizer during the fourth quarter valued at about $226,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE PFE opened at $26.13 on Tuesday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The stock has a 50-day moving average of $26.15 and a 200 day moving average of $27.02. The stock has a market capitalization of $148.21 billion, a price-to-earnings ratio of 18.53, a PEG ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm’s revenue for the quarter was up 24.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.10 EPS. Sell-side analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently commented on PFE. UBS Group reduced their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Truist Financial reduced their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. Citigroup lowered their target price on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Finally, Bank of America reaffirmed a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Pfizer has a consensus rating of “Moderate Buy” and a consensus price target of $31.92.

Insider Activity at Pfizer

In other news, Director Ronald E. Blaylock bought 19,457 shares of Pfizer stock in a transaction on Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.06% of the stock is currently owned by corporate insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.